Lv4
705 积分 2022-04-28 加入
Durable response to Olaparib in EGFR and somatic BRCA2-mutated lung adenocarcinoma with leptomeningeal metastases: a case report
2天前
已完结
Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis
9天前
已完结
Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer
9天前
已完结
Differentiation-related genes in tumor-associated macrophages as potential prognostic biomarkers in non-small cell lung cancer
9天前
已完结
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
19天前
已完结
Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden
21天前
已完结
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
21天前
已完结
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC)
22天前
已关闭
Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit
22天前
已完结
Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors
22天前
已完结
皖公网安备34019202002308
